about
sameAs
Investigation of biofilm formation in clinical isolates of Staphylococcus aureusFactors contributing to the biofilm-deficient phenotype of Staphylococcus aureus sarA mutants.Comparative genomics of Staphylococcus aureus musculoskeletal isolates.Inter- and intraspecies metabolite exchange promotes virulence of antibiotic-resistant Staphylococcus aureus.Iron in infection and immunity.A secreted bacterial protease tailors the Staphylococcus aureus virulence repertoire to modulate bone remodeling during osteomyelitis.Two heme-dependent terminal oxidases power Staphylococcus aureus organ-specific colonization of the vertebrate host.Impact of sarA and Phenol-Soluble Modulins on the Pathogenesis of Osteomyelitis in Diverse Clinical Isolates of Staphylococcus aureus.Repurposing the Nonsteroidal Anti-inflammatory Drug Diflunisal as an Osteoprotective, Antivirulence Therapy for Staphylococcus aureus Osteomyelitis.Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity.Analysis of the Staphylococcus aureus abscess proteome identifies antimicrobial host proteins and bacterial stress responses at the host-pathogen interface.Advances in the local and targeted delivery of anti-infective agents for management of osteomyelitis.Impact of oleic acid (cis-9-octadecenoic acid) on bacterial viability and biofilm production in Staphylococcus aureus.Recent advances in experimental models of osteomyelitis.Transcriptional profiling of a Staphylococcus aureus clinical isolate and its isogenic agr and sarA mutants reveals global differences in comparison to the laboratory strain RN6390.Validation of two vancomycin nomograms in patients 10 years of age and older.Staphylococcus aureus protein A enhances osteoclastogenesis via TNFR1 and EGFR signaling.Integrated molecular imaging reveals tissue heterogeneity driving host-pathogen interactions.Investigation of biofilm formation in clinical isolates of Staphylococcus aureus.Should antibiotics be discontinued at 48 hours for negative late-onset sepsis evaluations in the neonatal intensive care unit?Innate Immunity to : Evolving Paradigms in Soft Tissue and Invasive InfectionsMyD88 and IL-1R signaling drive antibacterial immunity and osteoclast-driven bone loss during Staphylococcus aureus osteomyelitisEarly TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent mannerAn Unusual Source of Sepsis in Two Previously Healthy ChildrenStaphylococcus aureus Osteomyelitis: Bone, Bugs, and SurgeryIdentification of Virulence Determinants During Host-Pathogen Interaction Using Tn-Seq TechnologyStaphylococcus aureus exhibits heterogeneous siderophore production within the vertebrate hostStaphylococcus aureus Infects Osteoclasts and Replicates IntracellularlyMicroLESA: Integrating Autofluorescence Microscopy, In Situ Micro-Digestions, and Liquid Extraction Surface Analysis for High Spatial Resolution Targeted Proteomic StudiesConcurrent local delivery of diflunisal limits bone destruction but fails to improve systemic vancomycin efficacy during Staphylococcus aureus osteomyelitisHost nutrient milieu drives an essential role for aspartate biosynthesis during invasive Staphylococcus aureus infection
P50
Q33306350-82F473B8-BD11-43C6-8F5D-BBF7FE93A4D5Q33375040-8E1C9EC2-F76C-4DBF-89A8-FBE363B5D621Q33699183-ACE4347D-6CC5-4340-87E5-3B8B11A5C7ABQ34339439-EDF1578C-CA7F-451C-93D2-382D20B33663Q36913895-CDF27438-D48B-4D41-A0C9-8EB5E322A015Q37042073-4C4CE82A-E695-4970-9049-3A6CE941C853Q37074711-81BAA840-63E7-4081-A074-58D01E8B1BC5Q37199881-BFB097B5-EDFF-4DDA-8D39-55E2F24E8F97Q37203711-CAA28DF5-69D1-45EF-8BC4-DA76168CB839Q37229481-35F94D13-38E5-4F46-8AC5-6700FBCA0269Q37424639-CDEBDDD9-F9D1-40BD-8BAA-B7F01A36A38CQ38610253-E478F752-1BEF-4B7F-A86C-804575EE756FQ43908742-CF1FB107-BC9A-4870-8AEE-1B6B1F880889Q43948023-70117965-F9FF-4399-BB68-E0B1CBC7ADBAQ44654590-2BB84A63-9A21-413C-BB46-0FE7D819B9BBQ46625916-8EBCA755-39E5-463E-B83E-64A13E15DB73Q51604886-8F37389E-F646-45AF-9E27-CE543B8AE6B4Q52355419-5FF9486B-6C27-47F1-A132-18FB4721B931Q53088217-73F62A06-02DA-42F4-8391-C6856B2FB4B1Q54159024-F39CFAE3-5542-4B60-BCCA-6BFCC1E78D48Q58209776-D398C45B-D80B-48E8-A62C-A7F2E92ED89AQ64052666-BA0ABADF-9096-41B1-A3FD-1FA5AFEDECD8Q88649847-7B0074D3-5937-47F8-A37F-9ECC3E502456Q89771030-278704B1-1355-4B07-8C25-C56AE692C6A6Q89865432-635A29AC-74DF-461A-963E-4382858205ADQ90117756-0FA24C7B-3235-4E69-BD43-F732E83C23ECQ90702219-1955DC5A-6DF0-4B14-8813-45E1752D3EC9Q90730528-0F68A6B3-9FAB-4312-A436-97AE75AE9AC9Q92436278-41CD2B74-642B-4154-9E32-9D461B891080Q93267157-7D897C80-6050-4DFA-BF1F-498AB9FFD994Q94947911-BE75E9F9-5C9E-41CD-A14E-7B41C8230635
P50
description
physician, researcher, and biomedical engineer
@en
name
James E. Cassat
@en
type
label
James E. Cassat
@en
altLabel
JE Cassat
@en
James E Cassat
@en
prefLabel
James E. Cassat
@en
P101
P106
P1416
P69
P1416
P21
P31
P496
0000-0002-1199-1167